COPB2 Antibody CDR Sequences for Severe COVID-19 Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting COVID-19, such as PCR, cannot predict the worsening of symptoms in infected individuals, and existing antibodies for COPB2 do not effectively detect this protein for diagnostic purposes.
Innovation Solution
Development of novel antibodies with specific CDR sequences that can bind to COPB2, including specific amino acid sequences for heavy and light chain CDRs, allowing for accurate detection of COPB2 protein.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If PCR testing is used to detect SARS-CoV-2 infection, then the presence or absence of infection can be determined, but the ability to predict subsequent worsening is lost
Solution Approach 1:
The patent segments the diagnostic approach by using PCR to detect viral presence while simultaneously measuring COPB2 protein levels as a separate biomarker. This segmentation allows each test to serve its specific function: PCR for infection confirmation and COPB2 for prognosis prediction, thereby resolving the contradiction between accurate infection detection and predictive capability.
Solution Approach 2:
The patent introduces COPB2 protein levels as an intermediary biomarker that bridges the gap between infection status and clinical outcome prediction. This intermediary provides additional information that neither PCR alone nor direct clinical observation can provide, enabling prediction of worsening while maintaining accurate infection detection.
2Adaptability or versatility
If existing antibodies are used for COPB2 detection, then general COPB2 detection is possible, but effective diagnostic detection for predicting severe COVID-19 is not achieved
Solution Approach 1:
The patent applies local quality by designing antibodies with specific CDR sequences optimized for detecting the particular conformation or epitope of COPB2 that is relevant to severe COVID-19 pathology. This localized optimization of antibody structure at the CDR region ensures high reliability for diagnostic purposes while maintaining overall COPB2 detection capability.
Solution Approach 2:
The patent changes the parameters of the antibody molecules by specifying particular CDR amino acid sequences that optimize binding affinity and specificity for COPB2 in the context of severe COVID-19. This parameter optimization transforms general COPB2 detection into a reliable diagnostic tool for predicting severe outcomes.
3Measurement precision
If novel antibodies with specific CDR sequences are developed, then accurate COPB2 detection for predicting severe COVID-19 is achieved, but the complexity of antibody characterization and production increases
Solution Approach 1:
The patent applies preliminary action by pre-defining the optimal CDR sequences through prior research and characterization. This preliminary work establishes the precise antibody structure needed for accurate COPB2 detection, allowing for streamlined production and reduced complexity in subsequent manufacturing and quality control processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel antibodies provide a means to specifically detect COPB2 protein, enabling improved diagnostic capabilities for predicting severe COVID-19 symptoms and potential complications.
Implementation Method 1
An antibody against coatomer protein complex subunit beta 2 (COPB2) or an antigen binding fragment thereof
Data Source
Figure 1~2
Figure 3
Figure 4
AI summary
Provided is an antibody against coatomer protein complex subunit beta 2 (CO PB2) or an antigen binding fragment thereof, comprising any of the following CDR sets (a) to (c): (a) heavy chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 1, heavy chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 2, heavy chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 3, light chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 4, light chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 5, and light chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 6, (b) heavy chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 7, heavy chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 8, heavy chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 9, light chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 10, light chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 11, and light chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 12, (c) heavy chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 13, heavy chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 14, heavy chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 15, light chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 16, light chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 17, and light chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 18.